ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Average Target Price of $25.00

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $25.00.

Several brokerages have commented on SPRY. Weiss Ratings lowered ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Leerink Partners set a $15.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, September 8th.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several hedge funds have recently bought and sold shares of SPRY. BlackRock Inc. bought a new stake in shares of ARS Pharmaceuticals in the 2nd quarter worth approximately $42,544,000. Rubric Capital Management LP grew its stake in shares of ARS Pharmaceuticals by 29.0% in the 1st quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock worth $64,240,000 after buying an additional 1,800,000 shares during the last quarter. ADAR1 Capital Management LLC increased its position in ARS Pharmaceuticals by 268.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,361,536 shares of the company’s stock valued at $10,933,000 after buying an additional 991,967 shares in the last quarter. Janney Montgomery Scott LLC increased its position in ARS Pharmaceuticals by 56.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 2,016,464 shares of the company’s stock valued at $16,192,000 after buying an additional 728,632 shares in the last quarter. Finally, Tejara Capital Ltd purchased a new position in ARS Pharmaceuticals during the second quarter valued at $4,862,000. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Performance

Shares of SPRY opened at $4.07 on Thursday. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. ARS Pharmaceuticals has a one year low of $3.98 and a one year high of $13.15. The company has a 50-day simple moving average of $5.26 and a two-hundred day simple moving average of $7.25. The firm has a market capitalization of $404.76 million, a PE ratio of -1.87 and a beta of 0.85.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). The firm had revenue of $33.66 million for the quarter, compared to analysts’ expectations of $31.32 million. ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. On average, analysts anticipate that ARS Pharmaceuticals will post -1.9 EPS for the current fiscal year.

Key Headlines Impacting ARS Pharmaceuticals

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Positive Sentiment: Sell-side analysts have reportedly assigned ARS Pharmaceuticals a “Moderate Buy” consensus rating, suggesting some analysts still see potential value despite the recent decline. ARS Pharmaceuticals Stock Now Rated Moderate Buy
• Neutral Sentiment: Several law firms reminded investors that October 5, 2026 is the deadline to seek appointment as lead plaintiff in a federal securities class action involving investors who purchased SPRY shares between March 9 and June 24, 2026. These announcements are largely duplicative and do not represent new operating or financial information from the company. Rosen Law Firm Deadline Reminder Bragar Eagel Deadline Reminder
• Negative Sentiment: A class-action lawsuit has been filed against ARS Pharmaceuticals and certain officers, alleging violations of federal securities laws and investor harm during the stated class period. The allegations have not been proven, but the litigation could create legal costs, management distraction, reputational risk and potential financial liabilities, weighing on investor sentiment. ARS Pharmaceuticals Class Action Announcement Kaplan Fox Class Action Reminder

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product, neffy, is an epinephrine nasal spray designed to provide a needle-free alternative to injectable epinephrine for the emergency treatment of type I allergic reactions, including anaphylaxis.

Neffy received approval from the U.S. Food and Drug Administration in 2024 for adults and children who meet the applicable weight requirements.